CiVentiChem, a provider of integrated chemistry services, has entered into a research and development collaboration with Tranzyme Pharma Inc., a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) disorders.

Under the terms of the agreement, CiVentiChem will provide research services in the areas of medicinal chemistry, custom compound synthesis and process development. CiVentiChem will provide services to Tranzyme from its facility in Research Triangle Park, NC, as well as through its subsidiary, Indus Biosciences, located in Hyderabad.

CiVentiChem has proven expertise in executing quality comprehensive services in the areas of discovery support, lead optimization, contract research, custom synthesis of APIs, intermediates & NMEs, process development, and cGMP manufacturing for pharmaceutical and biotechnology companies. CiVentiChem will apply its expertise with the goal of accelerating the development of Tranzyme’s novel small molecule products for the treatment of post-operative ileus, gastroparesis, and other GI disorders. Financial details of the agreement were not disclosed.

"We are very pleased that Tranzyme Pharma has chosen CiVentiChem and Indus Biosciences for our value-added services in process development and custom chemistry to complement their internal capabilities,” said Bhaskar Venepalli, president for CiVentiChem.

“CiVentiChem’s aim in this collaboration is to support Tranzyme in its small molecule programs by increasing productivity and shortening the time required for product development,” Venepalli added.

“We selected CiVentiChem for its ability to consistently design and implement complex chemistry on demand while delivering quality results,” said Mark L. Peterson, vice- president of Operations for Tranzyme Pharma.

“CiVentiChem offers us a unique advantage by leveraging extensive chemistry expertise in India through its operations in Hyderabad. We look forward to their continued involvement in our drug development programs,” Peterson added.

Tranzyme is a biopharmaceutical company developing novel orally bioavailable, small molecule therapeutics for the treatment of gastrointestinal (GI) diseases.